Keystone Wealth Services LLC Sells 305 Shares of Bristol-Myers Squibb (NYSE:BMY)

Keystone Wealth Services LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,201 shares of the biopharmaceutical company’s stock after selling 305 shares during the quarter. Keystone Wealth Services LLC’s holdings in Bristol-Myers Squibb were worth $321,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Swedbank AB raised its stake in shares of Bristol-Myers Squibb by 0.9% during the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock valued at $162,440,000 after purchasing an additional 28,427 shares during the period. Zhang Financial LLC purchased a new position in Bristol-Myers Squibb during the third quarter worth about $212,000. Occidental Asset Management LLC grew its position in Bristol-Myers Squibb by 9.7% during the third quarter. Occidental Asset Management LLC now owns 10,021 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 886 shares in the last quarter. Cornell Pochily Investment Advisors Inc. grew its position in Bristol-Myers Squibb by 2.0% during the third quarter. Cornell Pochily Investment Advisors Inc. now owns 14,298 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 285 shares in the last quarter. Finally, CX Institutional grew its position in Bristol-Myers Squibb by 81.1% during the third quarter. CX Institutional now owns 132,035 shares of the biopharmaceutical company’s stock worth $6,832,000 after buying an additional 59,116 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BMY shares. BMO Capital Markets restated a “market perform” rating and set a $48.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. UBS Group upped their price objective on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Jefferies Financial Group upped their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. TD Cowen upped their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 16th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $53.00.

Bristol-Myers Squibb Trading Up 0.2 %

BMY opened at $52.76 on Wednesday. The business has a 50 day simple moving average of $49.97 and a two-hundred day simple moving average of $46.32. The firm has a market capitalization of $106.95 billion, a price-to-earnings ratio of -17.02, a PEG ratio of 13.75 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $57.65.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the company earned $1.75 EPS. The business’s revenue was up 8.7% compared to the same quarter last year. Analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.55%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.